9h agoThe FlyBEARISH 34General
Archived explainer. For the current picture see today's ORIC page.
Why Is ORIC PHARMACEUTICALS (ORIC) Stock Down Today?
By the Top Tier Newswire AI Desk · October 26, 2026 at 2:53 PM ET · reviewed against 3 wire stories
ORIC PHARMACEUTICALS (ORIC) is down -28.70% in the latest session. Our newswire has captured 3 stories on ORIC across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Oric Pharmaceuticals shares fell 28.70% to close at $9.39. The primary driver was the presentation of new prostate cancer drug data by Johnson & Johnson, which weighed on the stock despite a recent price target increase from Stifel.
What Happened
The stock opened at $12.90, a 2.1% gap down from the prior close of $13.17. It reached a session high of $13.23 at 9:30 AM ET before sliding to a session low of $9.29 at 2:50 PM ET. Stifel raised its price target on Oric Pharmaceuticals to $18 from $14, maintaining a Buy rating. This move followed the company's presentation of preclinical data for rinzimetostat at the ESMO Congress 2026. Additionally, Oric announced plans to advance enozertinib to a Phase 3 trial, citing an 84% confirmed systemic objective response rate and a 70% confirmed intracranial objective response rate in Phase 1b data. The company plans to launch the global Phase 3 Redwood-1 trial of enozertinib in first-line EGFR atypical NSCLC in the first half of 2027.
What The Data Shows
Trading volume reached 3.9 million shares, which is 2.6 times the three-month daily average. The stock printed 48 fresh 52-week lows on October 26, 2026. The 52-week range is $7.23 to $14.68. The company has a market capitalization of $1.4 billion and is unprofitable, with trailing twelve-month earnings per share of negative $1.35. The beta is 0.98. Recent insider activity includes six sales totaling $1.7 million over the last 90 days, with no buys. Dominic Piscitelli, the CFO, sold shares on October 20, 2026, and September 28, 2026. Richard A. Heyman, a director, sold shares on October 1, 2026.
What To Watch
Investors will monitor the upcoming global Phase 3 Redwood-1 trial of enozertinib, which is scheduled to begin in the first half of 2027.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ORIC by the numbers
Last: $9.39Session: -28.70%Coverage: 3 stories / 2 sourcesAI sentiment: 54/100 (mixed)Mkt cap: $1.4B52w: $7.23 to $14.68
The headlines behind the move
13h agoThe FlyBULLISH 64Analyst
Oric Pharmaceuticals price target raised to $18 from $14 at Stifel
1d agoInvesting.com Analyst RatingsBULLISH 64Analyst
Stifel raises ORIC Pharmaceuticals price target to $18 on ESMO data
Stifel raises ORIC Pharmaceuticals price target to $18 on ESMO data
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ORIC: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ORIC move explainers: 2026-10-26 · 2026-10-23 · 2026-10-20